---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-265612"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2024-11-26T23:59:59+00:00"
generated_at: "2026-05-29T17:43:42.410017+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# KalVista appoints Laurence Reid, Ph.D. to Board of Directors

## Summary
- Laurence Reid appointed to KalVista Board effective Nov 23, 2024; term expires at 2027 annual meeting.
- Compensation: initial option for 17,000 shares, $42,500 annual cash retainer, annual option for 10,000 shares.
- Reid brings over 30 years biotech experience; was CEO of Decibel Therapeutics prior to Regeneron acquisition.
- Reid's appointment comes as KalVista progresses sebetralstat toward FDA PDUFA date of June 17, 2025.
- Board determined Reid independent under Nasdaq rules.

## SEC filing metadata
- accession: 0001193125-24-265612
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2024-11-26T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000119312524265612/0001193125-24-265612-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000119312524265612/d851354d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-265612
- JSON: https://secwatch.observer/filing/0001193125-24-265612.json
- Plain text: https://secwatch.observer/filing/0001193125-24-265612.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.